ATXS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATXS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Astria Therapeutics's change in inventory for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Astria Therapeutics's inventory stayed the same from Sep. 2023 to Dec. 2023 .
Astria Therapeutics's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Astria Therapeutics's inventory stayed the same from Dec. 2022 to Dec. 2023 .
Astria Therapeutics's Total Inventories for the quarter that ended in Dec. 2023 was $0.00 Mil.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The historical data trend for Astria Therapeutics's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astria Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Change In Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
Astria Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Change In Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astria Therapeutics (NAS:ATXS) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Astria Therapeutics's Days Inventory for the quarter that ended in is calculated as:
Days Inventory | = | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period |
= | 0 | / | 0 | * | 365 / 4 | |
= | N/A |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
Astria Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 0 | / | 0 | |
= | N/A |
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Astria Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 0 | / | 0 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Astria Therapeutics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Perceptive Life Sciences Master Fund Ltd | director, 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Andrea Matthews | officer: Chief Business Officer | C/O ASTRIA THERAPEUTICS, INC., 75 STATE STREET, SUITE 1400, BOSTON MA 02109 |
Christopher Morabito | officer: Chief Medical Officer | C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Andrew Komjathy | officer: Chief Commercial Officer | CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B14202, CAMBRIDGE MA 02139 |
Andrew John Nichols | officer: Chief Scientific Officer | C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG 1400E, CAMBRIDGE MA 02139 |
Perceptive Xontogeny Venture Fund, Lp | director, 10 percent owner | C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Jonathan Violin | director | 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087 |
Fred Callori | director | 100 HIGH STREET, 28TH FLOOR, BOSTON MA 02110 |
Xontogeny, Llc | director, 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Perceptive Advisors Llc | director, 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Joseph Edelman | director, 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Joanne T. Beck | director | C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ, BLD. 1400E, SUITE B14202, CAMBRIDGE MA 02139 |
Anthony Gregg Lapointe | director | PO BOX 83216, GAITHERSBURG MD 20883-3216 |
Hugh M Cole | director | C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Benjamin Harshbarger | officer: Secretary and General Counsel | ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142 |
From GuruFocus
By Business Wire • 07-06-2023
By Business Wire Business Wire • 05-11-2023
By Business Wire • 08-02-2023
By PRNewswire PRNewswire • 03-02-2023
By Business Wire • 11-13-2023
By Business Wire • 08-07-2023
By Business Wire • 08-25-2023
By Business Wire Business Wire • 03-22-2023
By Business Wire • 12-04-2023
By Business Wire • 11-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.